SHARE

NanoTech Entertainment, Inc. (OTCMKTS:NTEK), a pioneer company in bringing the 4K ultra HD experience to consumers, reported a licensing deal with Film Karavan, the major distributor of famous Indian films. With the deal, UltraFlix™, company’s 4K Ultra HD network, has received the distribution rights to the distributor’s library of movies as well as ongoing new movie launches from their Film Associates around the Globe.

Film Karavan develops, produces, distributes and promotes South Asian specialty movies for a global audience. They foster and demonstrate revolutionary cinema of the subcontinent through exceptional platforms and events.

The details

4K Studios which is a NanoTech subsidiary firm with facilities in Hollywood and San Francisco, is in the course of digitally re-mastering the movies so that audience can get immersive high quality 4K Ultra HD viewing. The recent news confirms the Bollywood hits being included in the UltraFlix growing library of 4K movie content.

The list of movies included on the 4k platform is Jab Tak Hai Jaan, One By Two and Fanaa in romance category, ISHAQZAADE, Kabhi Khushi Kabhie Gham and Mohabbatein in drama segment, EK Tha Tiger, Agneepath and Gunday as Action Thrillers, DARR @ The Mall, Dhoom:3 and Kahaani under horror segment and Oh My God, Hum Tum and Andaz Apna Apna in comedy section.

The expert speaks

Aaron Taylor, NanoTech’s Executive VP of Sales and Marketing said that Film Karavan belongs to the list of the most successful and recognized distributors of top grossing Indian movies for years. With an extended catalog of top quality Indian movies and well-set Film Studio associations, the company is adding a number of quality movies to the UltraFlix Network.

The management is excited about associating with Film Karavan as the viewers can get access to a wide variety of films from the rapidly expanding Indian genre. The movies will be digitally re-mastered by subsidiary 4K Studios.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of journaltranscript.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

https://www.journaltranscript.com/disclaimer

LEAVE A REPLY